Investor Relations
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 13, 2021Company CEO and CFO will also be conducting a presentation that will be available on-demand
-
Sep 8, 2021Peer-reviewed results describe the Company's test being used to confirm the presence of the virus on community waste, including mutated strains
-
Aug 12, 2021Solid quarterly results highlighted by revenue of $27.4 million, pre-tax income of $11.9 million and diluted EPS of $0.33
-
May 13, 2021Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million and diluted EPS of $0.26
-
Apr 28, 2021Times of India article highlights CoSara's tireless efforts to increase manufacturing of COVID-19 tests in response to deadly wave of infections
-
Apr 20, 2021Paper published in the Journal of Medical Microbiology utilizes Company's test in rapidly deployable mobile molecular diagnostics
-
Mar 25, 2021Record quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million
-
Mar 2, 2021Proprietary platform includes countertop device being developed for Co-Diagnostics by world experts in rapid PCR
-
Feb 25, 2021Clinical Reference Laboratory's FDA-authorized saliva-based PCR test uses technology developed by Co-Diagnostics to detect SARS-CoV-2
-
Feb 23, 2021Company also elevates in-house Senior VP of Biochemistry to Chief Scientific Officer
-
Feb 16, 2021Company believes direct saliva to play a key role in high throughput, point of care, and at home applications
-
Jan 28, 2021The Company's Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test is designed to reduce sample processing time and cost by eliminating the extraction process
-
Dec 22, 2020Proprietary Company design process facilitates rapid response in detecting mutation of a new coronavirus strain circulating in the UK
-
Dec 14, 2020Company anticipates Q4 revenue will significantly exceed previous quarter
-
Nov 17, 2020New tests expand global reach of Company COVID-19 test menu
-
Nov 16, 2020Company also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests
-
Sep 24, 2020Company expects to begin taking orders from US CLIA labs first week of October 2020
-
Sep 1, 2020
-
Aug 13, 2020Company reports robust sales of COVID-19 tests and net income per common share of $0.43
-
May 26, 2020Tissue from presymptomatic patient in Italy was found to contain SARS-CoV-2 using Company’s Logix Smart™ COVID-19 test kit
-
May 14, 2020Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter
-
Mar 20, 2020Company accelerates U.S. sales of COVID-19 test pursuant to new FDA policy
-
Feb 24, 2020Logix Smart™ COVID-19 Test now available for export from the United States as a CE-marked IVD
-
Feb 20, 2020Company’s new Logix Smart™ COVID-19 Test expected to be available with CE marking in February 2020
-
Feb 6, 2020Product launch and rapid development of the Logix Smart™ 2019-nCoV coronavirus test facilitated by Company’s proprietary technology platform
-
Feb 4, 2020Coronavirus assay will be addressed in webinar, as well as development of an innovative multiplex application of Company’s technology for mosquito populations
-
Jan 31, 2020Components of recently designed novel coronavirus assay have successfully passed initial verification
-
Jan 30, 2020Co-Diagnostics Inc CEO Interviewed on Fox Business with Maria Bartiromo as Coronavirus Concerns RiseInterviews on Fox Business and other programs discussed issues surrounding the novel strain of the coronavirus and the Company’s plan to provide a diagnostic solution
-
Jan 29, 2020
-
Jan 28, 2020Interview covered method of transmission, importance of accurate diagnostic tools, and the Company diagnostic announced last week
-
Jan 23, 2020Proprietary Company design process facilitates rapid response to health emergencies
-
Jan 14, 2020Co-Diagnostics’ CoPrimer platform, licensed by LGC, Biosearch, successfully used by Bayer to develop assays for multiplex PCR
-
Jan 2, 2020CoSara tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus recently granted regulatory approval by CDSCO to formally launch at India Diagnostic Expo
-
Dec 10, 2019Vector Smart™ NAM-e multiplex PCR test to provide proactive defense against mosquito populations carrying the deadly eastern equine encephalitis virus
-
Dec 3, 2019CoSara Saragene™ tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus now available for sale and distribution as in vitro diagnostics
-
Nov 13, 2019Revenue includes sales of infectious disease, mosquito abatement products and AgBio primer design services
-
Oct 29, 2019Company completes sale and installation to one of the largest private molecular diagnostics labs in Ghana
-
Oct 15, 2019Vector Smart™ products being presented at 6 vector control conferences in October to prepare for 2020 mosquito season
-
Oct 10, 2019Vector Smart™ ZDC multiplex PCR test to aid prevention of tropical disease proliferation in the US and abroad
-
Sep 19, 2019Company will host booth to introduce and promote mosquito abatement products to midwestern states in Tulsa, OK on Sept 19-20
-
Sep 4, 2019Expansion to include increased royalties and cover additional applications for Company’s technology platform
-
Aug 21, 2019Event to include demos and training for distributors and end-users of Company’s products
-
Aug 14, 2019Q2 revenue reflects increase over Q1, as US sales of mosquito abatement products and AgBio primer design services gain momentum